These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12561697)

  • 1. On target. A new generation of drugs offers customized cures.
    Fischman J
    US News World Rep; 2003 Jan; 134(2):50-2, 55-6, 58. PubMed ID: 12561697
    [No Abstract]   [Full Text] [Related]  

  • 2. [Target molecules of molecular target therapy of cancer].
    Uehara Y
    Nihon Rinsho; 2004 Jul; 62(7):1206-8. PubMed ID: 15283134
    [No Abstract]   [Full Text] [Related]  

  • 3. GlaxoSmithKline cancer drug threatens Herceptin market.
    Waltz E
    Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
    [No Abstract]   [Full Text] [Related]  

  • 4. The EGF receptor family as targets for cancer therapy.
    Mendelsohn J; Baselga J
    Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Targeted therapies for lung cancer].
    Tamura K
    Rinsho Ketsueki; 2008 Aug; 49(8):616-21. PubMed ID: 18800610
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeted therapies in breast cancer: challenging questions from oncology nurses.
    Becze E
    ONS Connect; 2007; 22(8 Suppl):31-2. PubMed ID: 17824554
    [No Abstract]   [Full Text] [Related]  

  • 7. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 8. [Angiogenesis and metastasis in colorectal cancer].
    Yamada K; Yamamura T; Yamaguchi S
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():97-101. PubMed ID: 14574863
    [No Abstract]   [Full Text] [Related]  

  • 9. Avastin-Tarceva combination fails in lung cancer.
    Jones D
    Nat Biotechnol; 2009 Feb; 27(2):108-9. PubMed ID: 19204674
    [No Abstract]   [Full Text] [Related]  

  • 10. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
    Tuma RS
    J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
    [No Abstract]   [Full Text] [Related]  

  • 11. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents.
    Holash J; Thurston G; Rudge JS; Yancopoulos GD; Adjei AA; Bergers G; Pytowski B; Pegram M; Gordon MS
    Cancer Metastasis Rev; 2006 Jun; 25(2):243-52. PubMed ID: 16770536
    [No Abstract]   [Full Text] [Related]  

  • 13. Reversing resistance to targeted therapy.
    Vidal L; Attard G; Kaye S; De Bono J
    J Chemother; 2004 Nov; 16 Suppl 4():7-12. PubMed ID: 15688600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Do informed patients live longer?].
    Jelitto HU
    Krankenpfl J; 2005; 43(4-6):142-3. PubMed ID: 16171085
    [No Abstract]   [Full Text] [Related]  

  • 15. [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
    Yamashita T; Iwata K
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2551-4. PubMed ID: 20104676
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
    Yan L; Beckman RA
    Biotechniques; 2005 Oct; 39(4):565-8. PubMed ID: 16235569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches in the management of lung cancer.
    Kris M
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S22-4. PubMed ID: 16280107
    [No Abstract]   [Full Text] [Related]  

  • 18. New oncology strategy: molecular targeting of cancer cells.
    Capriotti T
    Medsurg Nurs; 2004 Jun; 13(3):191-5. PubMed ID: 15219169
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.
    Longo R; D'Andrea M; Sarmiento R; Gasparini G
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S41-50. PubMed ID: 20374029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing targeted therapies for lung cancer.
    Gandara DR
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):648-9, 690. PubMed ID: 16258461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.